Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma

Abstract

The postoperative monitoring of CEA and CA125 provided prognostic significance to the measurement of CA19-9 in pancreatic cancer after resection.

Preoperative neutrophili-to-lymphocyte ratio is useful for stratifying the prognosis of tumor markers-negative pancreatic cancer patients

“…Preoperative TM, particularly CA19-9, was a strong prognostic factor of the postoperative survival of patients with PC. 10,11 However, based on our aforementioned data, patients with negative TMs still had severe postoperative results, of which 30% had survived after 5 years. Postoperative prognostication using TMs has two significant limitations.…”

“…Preoperative serum CA19-9 level is positively associated with tumor metastasis, and an elevated CA19-9 level is correlated to early recurrence and death. 10,11 However, serum CA19-9 level alone is not sufficient in predicting postoperative survival because it is usually elevated in case of biliary obstruction. 12 In addition, approximately 5%e10% of the population are Lewis negative individuals, and they are documented to have scarce or no CA19-9 secretion.…”

“…12 Some reports have shown that carcinoembryonic antigen (CEA) was a potential biomarkers for PC, 13 particularly in the case of normal CA19-9 value. 11 However, the predictive power of CEA in patients with PC was not adequate 10 , 13 systemic inflammatory markers (SIM), such as the neutrophil-to-lymphocyte ratio (NLR), Glasgow prognostic score (GPS), platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), or controlling nutritional status (CONUT) score, have been useful for the prognostication of patients with various cancers, such as nasopharyngeal cancer, non-small cell lung cancer, or upper tract urothelial cancer. 14e16 However, whether these systems are applicable to patients with PC who presented with negative tumor marker (TM) levels remains unclear.…”

Serum CA242: a biomarker for diagnosis, progression, and metastasis in multiple tumors

“…We found that CA242 levels were elevated in a variety of digestive system cancers, including pancreatic cancer, gallbladder cancer, cholangiocarcinoma, colorectal cancer, and gastric cancer, which was consistent with previous reports. The AUC values of the ROC curves for pancreatic cancer, gallbladder carcinoma, and cholangiocarcinoma were all greater than 0.8, but only pancreatic cancer has been studied in detail [4,10,13,17,22,[25][26][27]. Previous studies have shown that CA242 alone or in combination with other biomarkers can predict the diagnosis, progression, and prognosis of pancreatic cancer [4, 7, 10, 12-16, 23, 24].…”

Serum CA242: a biomarker for diagnosis, progression, and metastasis in multiple tumors

“…Currently, although CA242 has been used as a rst-line clinical marker of pancreatic cancer for more than a decade [11], research on it has continued. CA242 is not merely a diagnostic predictor [12,13] but also participates in forecasting the progression and prognosis of many tumors [14][15][16]. In pancreatic cancer, colorectal cancer [17][18][19], gastric cancer [20,21] and other tumors and when used alone or in combination with CA19-9, CA50, CEA and other biomarkers [4,7,14,[22][23][24], CA242 is gradually becoming better understood and applied more broadly.…”